These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12506177)

  • 1. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.
    Rini BI; Weinberg V; Bok R; Small EJ
    J Clin Oncol; 2003 Jan; 21(1):99-105. PubMed ID: 12506177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
    Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
    Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
    Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
    J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
    Amato RJ; Hernandez-McClain J; Henary H
    Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
    Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
    BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
    Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
    Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
    Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of GM-CSF in advanced prostate cancer.
    Dreicer R; See WA; Klein EA
    Invest New Drugs; 2001; 19(3):261-5. PubMed ID: 11561685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
    Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
    Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
    Sonpavde G; Aparicio AM; Zhan F; North B; Delaune R; Garbo LE; Rousey SR; Weinstein RE; Xiao L; Boehm KA; Asmar L; Fleming MT; Galsky MD; Berry WR; Von Hoff DD
    Urol Oncol; 2011; 29(6):682-9. PubMed ID: 19959380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer.
    Si T; Guo Z; Hao X
    J Immunother; 2009 Jan; 32(1):86-91. PubMed ID: 19307997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer.
    Dreicer R; Klein EA; Elson P; Peereboom D; Byzova T; Plow EF
    Urol Oncol; 2005; 23(2):82-6. PubMed ID: 15869991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.